Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trial.

•Safe, effective and more affordable pneumococcal conjugate vaccines (PCV) are needed.•This new PCV targets serotypes most likely to cause disease in low- and middle-income countries.•The vaccine was safe and immunogenic in adults, toddlers and infants in this phase 1/2 trial.•The data support progression to a phase 3 licensure trial of the new PCV.